
Ezekiel Weis
Elementy, w których Ezekiel Weis uczestniczy
czwartek 9 czerwca, 2022
piątek 10 czerwca, 2022
Learning Objectives:At the end of this session participants will be able to:• Integrate new research techniques and ideas in managing Oculoplastics conditions. CanMeds Roles: Medical Expert, Collaborator
Elementy, w których Ezekiel Weis attends
czwartek 15 czerwca, 2023
Admission to this session is included in the full registration fee. If you wish to attend this session as a stand-alone event only, please contact Rita Afeltra at rafeltra@cos-sco.ca to register.
piątek 16 czerwca, 2023
Learning Objectives: At the end of this session, participants will be able to: Recognize orbital imaging findings of ocular conditions and surgeriesDescribe the various medical management options for Thyroid Eye DiseaseManage infections of...
Learning Objectives: At the end of this session, participants will be able to: Integrate novel research ideas into clinical practice Describe key research outcomes in oculoplastics CanMEDS Roles: Scholar, Medical ExpertX
Learning Objectives: At the end of this session, participants will be able to: Integrate oncological principles in the management of oculoplastics disordersCanMEDS Roles: Medical Expert, Professional
czwartek 19 czerwca, 2025
Additional authors: Ezekiel Weis, Guy Negretti, Mandeep Sagoo
Additional authors: Andrzej Kulaga, Ezekiel Weis, Kris Langdon, Alex Ragan Fiona Costello
piątek 20 czerwca, 2025
Author’s Name(s): Kimberly Papp, Samuel Baugh, Ezekiel Weis, Robert Goldberg, Kelsey RoelofsAuthor’s Disclosure Block: Kimberly Papp, none; Samuel Baugh, none; Ezekiel Weis, none; Robert Goldberg, none; Kelsey Roelofs, Dr. Roelofs is a consultant for Amgen.Abstract BodyPurpose: To investigate the rate of transformation of eyelid lentigo maligna (LM) to invasive melanoma and to assess the impact of surgical management on dise...
sobota 21 czerwca, 2025
Learning Objectives: At the end of this session, participants will be able to:Describe recent advances in the diagnosis and treatment of intraocular and extraocular ophthalmic tumors, tailored to the needs of general ophthalmologists and ocular oncologists.